Clinical Stage Pharma

Developing small molecules for the treatment of gastric acid related diseases.

About Cinclus Pharma
Cinclus Pharma

The Next Leap Forward

Blockbuster Proton Pump Inhibitors (PPIs) such as Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. The time has now come for Potassium-Competitive Acid Blockers (P-CABs) to take the next leap forward in the treatment of acid-related diseases. Cinclus Pharma’s clinical stage drug candidate linaprazan glurate takes a new approach to provide improved management of GERD and for the treatment of Helicobacter Pylori (H.Pylori) infection.

Learn more

Cinclus Pharma man with GERD startpage

Latest pressreleases

cinclus pharma illustration of linazapran molecule grey
Our lead asset

Linaprazan glurate

Built on world-leading industrial tradition, linaprazan glurate is a gastric acid blocker and therapy with great potential for healing GERD. Several clinical Phase I trials are successfully completed and in 2022 the clinical Phase II trial was completed. Linaprazan glurate represents an improved mode of action with the potential for superior clinical efficacy and beneficial pharmacokinetic profile compared to PPIs.

Learn more

Latest News

Cinclus Lennart Hansson 02

Lennart Hansson, visionary and experienced Chairman of the Board

Cinclus Pharma's co-founder and Chairman of the Board, Lennart Hansson, has long experience from leading positions at various biotech and pharmaceutical companies. He has also worked at AstraZeneca on gastrointestinal diseases and has served on more…

Cinclus News Christer Finansieringsevent 02

Cinclus Pharma at ABGSC - Life Science Summit 2023

Christer Ahlberg, CEO of Cinclus Pharma, was invited to present the company's latest updates and the development of linaprazan glurate at the ABGSC Life Science Summit on May 30-31, 2023.

Cinclus Nina

Nina Rawal at Trill Impact Ventures on the investment in Cinclus Pharma

The Investment company Trill Impact sees Cinclus Pharma as a strong card. Nina Rawal, Co-Head of Ventures, sits on the board of Cinclus Pharma, where her biomedical experience and expertise in financing comes in handy.

cinclus pharma bistro with greenery in the ceiling
Reflux diseases


Most people can relate to discomfort from heartburn and regurgitation, two of the most common symptoms caused by GERD. Symptoms often occur during or after eating and drinking, which affects both motivation and the ability to enjoy social activities such as picnics, dinners, events, or just a cup of coffee with friends. More severe stages of GERD with the presence of esophageal erosions (eGERD) or ulcerations (complicated GERD) can be very painful.

Learn more about GERD

"Cinclus Pharma wants to accomplish a paradigm shift in the treatment of acid-related diseases. We will do this by registering and launching our effective P-CAB linaprazan glurate and making it available worldwide."